Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia is feasible in clinical practice based on recently published international recommendations. Nevertheless, factors predictive of molecular recurrence have not been fully elucidated and long-term follow-up of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Dulucq, Stéphanie, Nicolini, Franck E., Rea, Delphine, Cony-Makhoul, Pascale, Charbonnier, Aude, Escoffre-Barbe, Martine, Coiteux, Valérie, Lenain, Pascal, Rigal-Huguet, Françoise, Liu, Jixing, Guerci-Bresler, Agnès, Legros, Laurence, Ianotto, Jean-Christophe, Gardembas, Martine, Turlure, Pascal, Dubruille, Viviane, Rousselot, Philippe, Martiniuc, Juliana, Jardel, Henry, Johnson-Ansah, Hyacinthe, Joly, Bertrand, Henni, Tawfiq, Cayssials, Emilie, Zunic, Patricia, Berger, Marc G., Villemagne, Bruno, Robbesyn, Fanny, Morisset, Stephane, Mahon, François-Xavier, Etienne, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Chronic Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713567/
https://www.ncbi.nlm.nih.gov/pubmed/35615931
http://dx.doi.org/10.3324/haematol.2022.280811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713567/
https://www.ncbi.nlm.nih.gov/pubmed/35615931
http://dx.doi.org/10.3324/haematol.2022.280811

Ejemplares similares